1276 — Jiangsu Hengrui Pharmaceuticals Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapFalling Star

Market Cap
HK$438.06bn
Enterprise Value
HK$392.42bn
Revenue
CNY31.63bn

Annual income statement for Jiangsu Hengrui Pharmaceuticals Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	25,906	21,275	22,820	27,985	31,629
Cost of Revenue
Gross Profit	22,150	17,772	19,257	24,104	27,249
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	21,242	17,163	17,910	20,499	22,645
Operating Profit	4,663	4,112	4,910	7,486	8,985
Gain / Loss on Sale of Assets
Other Net Non Operating Costs
Net Income Before Taxes	4,466	3,968	4,667	7,170	8,708
Provision for Income Taxes
Net Income After Taxes	4,484	3,815	4,278	6,337	7,717
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,530	3,906	4,302	6,337	7,711
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,530	3,906	4,302	6,337	7,711
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.71	0.624	0.691	1	1.19
Dividends per Share